PMID- 29661026
OWN - NLM
STAT- MEDLINE
DCOM- 20191021
LR  - 20220408
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 34
IP  - 8
DP  - 2018 Aug
TI  - Patient perceptions of injection devices used with dulaglutide and liraglutide 
      for treatment of type 2 diabetes.
PG  - 1457-1464
LID - 10.1080/03007995.2018.1465903 [doi]
AB  - OBJECTIVE: Liraglutide and dulaglutide have demonstrated similar glycemic 
      efficacy and safety. However, they differ in treatment administration and 
      injection devices. The purpose of this study was to examine and compare patient 
      perceptions of the injection devices used with liraglutide and dulaglutide. 
      METHODS: Patients with type 2 diabetes treated with liraglutide or dulaglutide 
      were recruited from across the US. Patients completed the Diabetes Injection 
      Device Experience Questionnaire (DID-EQ) to rate their current injection device. 
      Patients who had experience with both treatments also completed the Diabetes 
      Injection Device Preference Questionnaire (DID-PQ) to report preferences between 
      the two devices. ANCOVAs were conducted to compare DID-EQ scores between 
      dulaglutide and liraglutide patients, while controlling for covariates. 
      Descriptive statistics are presented for preferences reported on the DID-PQ. 
      RESULTS: A total of 404 patients were recruited from 49 states (mean age = 60.7 
      years; 54.0% female; 204 liraglutide; 200 dulaglutide). Mean DID-EQ item scores 
      for both treatments were high, ranging from 3.48 to 3.90 on a 4 point scale. 
      ANCOVAs found significantly higher scores for dulaglutide than liraglutide on 
      DID-EQ global items assessing ease of use (3.82 vs. 3.73, p = .040) and 
      convenience (3.79 vs. 3.66, p = .004). Among the 58 patients who had used both 
      devices, more patients reported a preference for the dulaglutide device than the 
      liraglutide device on every item of the DID-PQ. CONCLUSIONS: High DID-EQ scores 
      indicate positive perceptions of both the liraglutide and dulaglutide injection 
      devices. The dulaglutide device was associated with slightly higher scores for 
      ease of use and convenience than the liraglutide device.
FAU - Matza, Louis S
AU  - Matza LS
AD  - a Patient-Centered Research, Evidera , Bethesda , MD , USA.
FAU - Boye, Kristina S
AU  - Boye KS
AD  - b Eli Lilly and Company , Indianapolis , IN , USA.
FAU - Currie, Brooke M
AU  - Currie BM
AD  - a Patient-Centered Research, Evidera , Bethesda , MD , USA.
FAU - Paczkowski, Rosirene
AU  - Paczkowski R
AD  - b Eli Lilly and Company , Indianapolis , IN , USA.
FAU - Lando, Laura F
AU  - Lando LF
AD  - b Eli Lilly and Company , Indianapolis , IN , USA.
FAU - Mody, Reema
AU  - Mody R
AD  - b Eli Lilly and Company , Indianapolis , IN , USA.
FAU - Jordan, Jessica
AU  - Jordan J
AD  - a Patient-Centered Research, Evidera , Bethesda , MD , USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20180514
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 839I73S42A (Liraglutide)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glucagon-Like Peptides/administration & dosage/*analogs & derivatives
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Immunoglobulin Fc Fragments/*administration & dosage
MH  - Injections/instrumentation
MH  - Liraglutide/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Perception
MH  - Recombinant Fusion Proteins/*administration & dosage
OTO - NOTNLM
OT  - Injection device
OT  - diabetes injection device experience questionnaire
OT  - diabetes injection device preference questionnaire
OT  - dulaglutide
OT  - liraglutide
OT  - type 2 diabetes
EDAT- 2018/04/18 06:00
MHDA- 2019/10/23 06:00
CRDT- 2018/04/18 06:00
PHST- 2018/04/18 06:00 [pubmed]
PHST- 2019/10/23 06:00 [medline]
PHST- 2018/04/18 06:00 [entrez]
AID - 10.1080/03007995.2018.1465903 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2018 Aug;34(8):1457-1464. doi: 10.1080/03007995.2018.1465903. 
      Epub 2018 May 14.